The SUMO pathway in pancreatic cancer: insights and inhibition

Christian Schneeweis1, Zonera Hassan1, Markus Schick2, Ulrich Keller2,3,4 and Günter Schneider2,3

An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells. The contribution of SUMOylation to transcriptional control, DNA repair pathways, mitotic progression, and oncogenic signalling has been described. Here we review functions of the SUMO pathway in PDAC, with a special focus on its connection to an aggressive subtype of the disease characterised by high MYC activity, and discuss SUMOylation inhibitors under development for precise PDAC therapies.

BACKGROUND

Although the introduction of active chemotherapeutic regimens such as FOLIRINOX and nab-paclitaxel with gemcitabine has considerably advanced the therapy of pancreatic ductal adenocarcinoma (PDAC),1 the 5-year survival rate of 9% for patients with this form of cancer remains unacceptably low.2 In addition to the substantial toxicities associated with these aggressive chemotherapeutic regimens, the low response rate in patients with metastatic disease underscores the need to develop new therapies.

PDAC heterogeneity, evident at numerous levels, is one substantial hurdle for the establishment of novel therapies. Two main subtypes of the disease have been consistently described: the basal-like subtype, which shows a strong overlap with the previously described squamous8 and quasi-mesenchymal subtypes,6 and the classical subtype.5 A 2020 study, which includes patients with advanced stages of the disease, further splits basal-like PDACs into basal-like A and basal-like B and the classical PDACs into a classical A and classical B type.6 Furthermore, a hybrid type of the disease showing expression of mRNAs belonging to identifier signatures of both main types has also been identified.5

Classical subtypes of PDAC show an enrichment for stage I/II disease, whereas the basal-like A subtype is enriched in metastatic disease and seems to be resistant to current chemotherapies.6 The basal-like subtype is characterised by activation of the MYC pathway together with pro-inflammatory pathways, hypoxia networks, metabolic reprogramming, autophagy, epidermal growth factor and transforming growth factor-β (TGF-β) signalling and activation of the ΔNp63 pathway,4 as well as being enriched in mutations in the tumour-suppressor TP53 and the lysine demethylase KDM6A and showing silencing of endodermal identity transcription factors, such as GATA6 or hepatocyte nuclear factor family members.3,6–11

The clear differences in the molecular underpinnings of the PDAC subtypes illustrate that understanding the biological mechanisms that drive these subtypes and connect the different subtypes with novel therapies represents one promising approach to improve the outcome of the disease.

Posttranslational modifications (PTMs) are dynamic, reversible enzymatic modifications that regulate processes such as protein folding, cellular and subcellular localisation, activity, stability, and interacting partners. PTMs can ensure quick adaption to the continuously stressful extrinsic and intrinsic conditions faced by cancer cells, and accordingly, PTM with ubiquitin and ubiquitin-like molecules such as small ubiquitin-like modifier (SUMO) and neural precursor cell expressed developmentally downregulated (NEDD) can contribute to the fitness of cancer cells.12–15 Similar to the process of ubiquitination, the ~11 kDa SUMO protein is covalently conjugated to cellular proteins15 by an enzymatic cascade mediated by the concerted action of the E1 SUMO-activating enzyme (SAE), the E2-conjugating enzyme, UBC9, and a limited set of E3 SUMO ligases (Fig. 1 and Box 1).

Thousands of cellular proteins can be SUMOylated18 to ensure a highly dynamic regulation of cellular functions, such as protein localisation, stability, interactions, as well as the activity of targets. The protective role of the SUMO pathway for cells exposed to various cell-intrinsic, including alterations in the cellular redox state or DNA damage, and cell-extrinsic stresses,13 like hypoxia, is reflected by the upregulation of SUMOylation in cancer cells.12 SUMOs are predominantly found within the nucleus, and SUMOylation has thus been assumed—and in many instances proven—to critically modulate cellular processes associated with this compartment,20 ranging from the control of transcriptional processes, DNA repair, and mitotic progression to the regulation
The SUMO pathway in pancreatic cancer: insights and inhibition

C Schneeweis et al.

**Fig. 1** SUMOylation: a tightly balanced attachment of SUMOs to substrates. Small ubiquitin-like modifier (SUMO) proteins 1–3 undergo a maturation step mediated by cleavage through sentrin-specific peptidases (SENP) to generate the C-terminal diglycine (GG) motif. In addition, SENPs ensure reversibility of SUMOylation and contribute to recycle SUMOs. The most intensively studied SUMO proteins are SUMO1, SUMO2, and SUMO3, where the homology of SUMO2 and SUMO3 is 97%. In an ATP-dependent process, SUMOs are transferred to the SUMO1-activating enzyme subunit 1 (SAE1)–SAE2 heterodimer. SUMOs are bound via a thioester bond to SAE2/UBA2. Subsequently, SUMO is transferred to the indispensable E2-conjugating enzyme of the cascade, UBC9 (UBE2I), again forming a thioester bond. With contribution of E3 ligases (e.g. from the PIAS family), SUMO is transferred to the e-amino group of lysine within protein targets via an isopeptide bond. Protein targets can be mono-, poly-, or multi-SUMOylated. The canonical functions of the pathway are depicted in Fig. 1.

**Box 1: SUMOylation: a highly dynamic posttranslational protein modification**

Small ubiquitin-like modifier (SUMO) proteins 1–3 undergo a maturation step mediated by cleavage through sentrin-specific peptidases (SENP) to generate the C-terminal diglycine (GG) motif. In addition, SENPs ensure reversibility of SUMOylation and contribute to recycle SUMOs. The most intensively studied SUMO proteins are SUMO1, SUMO2, and SUMO3, where the homology of SUMO2 and SUMO3 is 97%. In an ATP-dependent process, SUMOs are transferred to the SUMO1-activating enzyme subunit 1 (SAE1)–SAE2 heterodimer. SUMOs are bound via a thioester bond to SAE2/UBA2. Subsequently, SUMO is transferred to the indispensable E2-conjugating enzyme of the cascade, UBC9 (UBE2I), again forming a thioester bond. With contribution of E3 ligases (e.g. from the PIAS family), SUMO is transferred to the e-amino group of lysine within protein targets via an isopeptide bond. Protein targets can be mono-, poly-, or multi-SUMOylated. The canonical functions of the pathway are depicted in Fig. 1.

of cancer-relevant signalling pathways such as those mediated by TGF-β or nuclear factor-κB (NFκB). However, although a clear enrichment of SUMOylation events in the nuclear compartment is documented, cytosolic and membrane proteins can also become SUMOylated, which can further contribute to cancer-relevant functions of the pathway.

The functions of the SUMO pathway in cancer have been reviewed elsewhere in detail, so we will focus in this article on the identified roles of the SUMO pathway in PDAC. We will describe the known functions of the SUMO pathway in PDAC and will summarise means and drugs to interfere with SUMOylation. We will explain how the SUMO pathway is connected to the MYC oncogene and how this relationship can be used to develop precise therapies by applying a concept of synthetic dosage lethality. Finally, we will describe future SUMO research directions to translate basic findings to the clinic.

**THE SUMO PATHWAY IN PDAC**

The SUMO pathway has not yet been extensively analysed in PDAC. However, the importance of the SUMO pathway in other tumour entities, such as leukaemia or lymphoma, or many solid cancers, including breast, colorectal, or lung cancers together with investigations of the pathway in PDAC carried out over the past decade, underscores the potential relevance of this pathway with regard to the development of targeted therapies. Tissue-based analysis and mRNA expression profiles have defined an aggressive PDAC subtype that shows evidence of hyperactivity of the core SUMO pathway and thereby links the SUMO pathway with less-differentiated PDACs—the basal-like subtype—and an unfavourable prognosis. Mechanistic studies in PDAC link the SUMO pathway in particular with the response towards chemotherapies and to mechanisms of treatment resistance.

Approximately 500 proteins were found to be modified by SUMO1 in untreated MiaPaCa2 human pancreatic cancer cells. Notably, treatment of PDAC cells with chemotherapy altered the SUMOylation state, and several target proteins became deSUMOylated or SUMOylated, underscoring the relevance of the pathway in cellular stress responses. Smad nuclear interacting protein 1 (SNIP1), for example, was found to be dynamically dere-SUMOylated in response to gemcitabine treatment; SNIP1 has a role in the survival of MiaPaC2 cells under acute therapeutic stress from gemcitabine treatment, which was found to depend on its SUMOylation.

Perturbed SUMOylation equilibria are common in drug-resistant PDAC phenotypes. Promyelocytic leukaemia protein (PML) nuclear bodies are known to be involved in the regulation of cellular processes that are relevant to tumour suppression, such as DNA repair and the DNA damage response (DDR). The function of these nuclear organelles has been shown to be dependent on the appropriate SUMOylation of the major structural component PML, and hypoSUMOylation of PML in PDAC cells was associated with increased activation of the NFκB pathway to mediate gemcitabine resistance and increased activation of the cAMP response element-binding pathway to mediate oxiplatin resistance. Importantly, a distinct heterogeneity of PML expression and PML SUMOylation was detected in patient-derived xenograft (PDX) models. A score integrating total PML expression and PML SUMOylation was positively correlated with patient survival. This observation was interpreted by the authors as indication for a decreased likelihood for responding to chemotherapy in the more aggressive, PML-score low population. To directly test PML as an indicator of chemotheraphy responsiveness, PDX-derived cell lines were investigated. Indeed, higher levels of secreted PML, determined by proteomic analysis of secretomes, were connected with increased drug sensitivity. Although PML containing extracellular vesicles was described, the value of PML and its SUMOylation status in secretomes as a diagnostic marker for therapy responsiveness awaits further validation.

In addition, the E3-type SUMO ligase PIAS4 (protein inhibitor of activated STAT protein 4) was shown to be overexpressed in PDAC tumours and cell lines. Targeting Pias4 by RNA interference reduced PDAC cell growth. Tumour cells are exposed to limited nutrient supply and hypoxia. Hypoxia is triggering adaptive signalling pathways to assure survival and rewiring of cellular metabolism, e.g. induction of glycolysis. The transcription factor hypoxia-inducible factor-1 (HIF1), composed of the hypoxia-regulated factor HIF1α and the constitutively expressed HIF1β, and the E3 ubiquitin ligase von Hippel–Lindau (VHL), which controls HIF1α protein abundance, are central regulators in this adaptive process. Under hypoxic conditions of PDAC cells, Pias4 contributes to SUMOylation and inactivation of VHL. This
molecular event is needed for the complete stabilisation of HIF1α in response to hypoxia. These data document the interaction of the SUMOylation- and hypoxia-triggered pathways in the context of PDAC, which further highlight the cross-signalling of both pathways at multiple levels.12

INHIBITORS OF THE SUMO PATHWAY

Although the SUMO pathway has been implicated in cancer, only a few drugs targeting SUMOylation have been developed so far. Consistent with the existence of an enzymatic cascade to transfer SUMOs to its targets, the SUMOylation machinery can be targeted at several levels (Fig. 2) as well as at the level of SUMO maturation.

Inhibitors of the E1 SUMO-activating enzyme

Several natural products have been described and used to target the SUMOylation pathway at the first activation step, which is executed by the E1 enzyme. Such compounds include ginkgolic acid and kerriamycin B, which have been shown to block the SAE complex (Fig. 2).29 Ginkgolic acid inhibits the growth of PDAC cell lines in the double-digit micromolar range in vitro and was also shown to be active in an in vivo xenograft model.30 However, mechanistically, ginkgolic acid was demonstrated to target a pathway driving lipogenesis; and any specific effects of ginkgolic acid on the SUMOylation machinery were not investigated in this study.30 The ginkgolic acid structural analogue anacardic acid and kerriamycin B, which have been shown to block the SAE complex have been described. No data for their efficacy in colon cancer xenografts.36

Inhibitors of the E2-conjugating enzyme

In addition to E1 inhibitors that form adducts with SUMOs, a novel covalent inhibitor, COH000, which binds to Cys30 of SAE2, has been developed and characterised. COH000 does not compete with SUMO1 or ATP for binding to SAE2 but instead blocks the adenylation of SUMO36 by inducing conformational changes in the enzyme, demonstrating an allosteric mode of action.35 Functioning in the micromolar range in in vitro models, this inhibitor has demonstrated preclinical efficacy in colon cancer xenografts.36

Potential SENP inhibitors?

As outlined earlier, the SUMOylation pathway is highly dynamic and reversible, and various SENPs ensure the deSUMOylation of target proteins and the recycling of SUMOs. Therefore, SENPs also represent candidates for pharmacological targeting, and synthetic inhibitors of these molecules are available.29 Despite conflicting data with respect to the overexpression of SENP1 in PDAC,38 SENP1 in prostate cancer cells,40 acts in the double-digit nanomolar range in PDAC cell lines and has been shown to activate checkpoint kinase 2 (CHK2) in drug-sensitive lines, leading to inhibition of cellular growth.41 However, the direct involvement of SENP1 in this triptolide-induced cellular response is unclear. Furthermore, triptolide, which is also potent in selected in vivo PDAC models,42 is known to target the ERCC3 helicase, a subunit of the transcription factor TFIIH to inhibit RNA polymerase II-dependent transcription. Therefore, the effects of triptolide on SENP1 seem rather indirect.

Inhibiting SUMO-dependent protein interactions

Another means of interfering with the SUMO pathway is to prevent the recognition and interpretation of the SUMO code. The information imparted by SUMOylation is recognised and translated into altered biology by non-covalent interaction with other proteins that harbour a specific motif, the SUMO-interacting motif (SIM). Affimer (Adhiron) technology—a system based on artificial non-antibody scaffold proteins—was used to demonstrate that synthetic proteins blocking SUMO-dependent protein–protein interactions in a SUMO-isoprotein-specific fashion can be developed.44 For readers who are not familiar with this technology,
The SUMO pathway in pancreatic cancer: insights and inhibition

C Schneweis et al.

534

please refer to refs. 45,46 Similarly, a SIM mimic peptide coupled to gold nanoparticles interacts with poly-SUMO-2/3 chains and inhibits poly-SUMO-2/3-dependent protein–protein interactions.47 The involvement of the SUMO pathway in the control of the DDR could explain how the gold nanoparticle SUMO-2/3 ligand sensitises cancer cells to irradiation.47 Although non-peptidomimetic small-molecule SUMO–SIM inhibitors are under development,48,49 the therapeutic value in the context of PDAC is currently not known.

MYC AND ITS CONNECTION WITH THE SUMO PATHWAY

The basic helix–loop–helix leucine zipper transcription factor MYC dimerises with MAX, another basic helix–loop–helix leucine zipper transcription factor, to bind to enhancer (E-) boxes in the promoters of numerous genes. As an oncoprotein, MYC controls the metabolism, growth, and proliferation of cancer cells.50 Witkiewicz and colleagues showed that amplification of MYC, which was found in around 14% of patients with PDAC in their study, is the sole copy number variation associated with the poor survival of PDAC patients.51 Furthermore, another study showed that MYC amplifications occur more frequently in liver metastasis (12%) than in primary pancreatic tumours (4%) and lung metastasis (6%), highlighting an important function of MYC along the route to liver metastasis.52 This observation is underscored by the demonstration that amplifications of MYC are positively selected for during tumour progression,53 as well as the finding that MYC activity is associated with the basal-like subtype of the disease.54,55 Therefore, targeting MYC and MYC-dependent pathways could offer opportunities for novel therapies for patients with advanced disease and very poor prognosis who might be resistant to currently established standard therapies. Potential approaches to target MYC in the context of PDAC, which include bromodomain and extra-terminal motif (BET) inhibitors or MYC-MAX dimerisation inhibitors, have been described previously,56,57 so we will focus here on the concept of MYC-associated synthetic lethality.58

Synthetic lethality

Synthetic lethality usually refers to the situation in which individually targeting each gene within a pair of genes is tolerated but the combined inactivation induces a dramatic loss of cancer cell fitness. Synthetic lethality can also occur between genes and small molecules, as exemplified by the sensitivity of tumour cells harboring mutations in the DNA repair gene BRCA1/2 to poly-ADP ribose polymerase (PARP) inhibitors and certain chemotherapies, such as platinum compounds.58,59 As the genetic lesion is restricted to cancer cells, therapeutic concepts based on synthetic lethality might open an exploitable therapeutic window. Indeed, the benefits of platinum therapy or PARP inhibition have been demonstrated in patients with BRCA1/2-mutated PDAC60–62 supporting the notion that synthetic lethality is relevant in PDAC and that there is a need for preclinical and clinical research to improve understanding of such concepts.

MYC and synthetic dosage lethal interaction

Notably, a specific kind of synthetic lethality, called synthetic dosage lethality, defines a situation in which hyperactivity of one gene generates a dependency on another gene product, and is relevant in the context of the MYC pathway. Similar to the situation for genetic lesions, the restriction of the hyperactivation to cancer cells provides an exploitable therapeutic opportunity. Accordingly, several unbiased genetic screens have validated the concept of synthetic lethality associated with the MYC protein family,7,63–70 and these screens have been supported by many observations that postulate a synthetic lethal relationship of MYC with the splicing machinery and the arginine methyltransferase PRMT5,71 CHK1,72 cyclin-dependent kinase 1/2,73,75 Aurora kinases,76–78 death-receptor engagement,79 PIM1,80,81 BET inhibition,82,83 polo-like kinase 1,84 the mitotic machinery,85,86 and protein homeostasis.87,88 These data suggest that MYC drives the cellular machineries that are responsible for splicing, protein homeostasis, transcription, replication, or mitosis, to a limit beyond which cells cannot cope with any additional stress targeting these particular processes. Therefore, MYC marks cancers with a specific set of therapeutic vulnerabilities, which should consequently facilitate the stratification of patients for precise therapeutic interventions.56

The MYC–SUMO connection

In 2012, an unbiased genetic screen demonstrated the synthetic lethality of the SUMO pathway components SAE1 and SAE2 with MYC,64 an observation subsequently corroborated in haematological malignancies89 and small cell lung cancer (SCLC).90 Across species, MYC-driven B cell lymphomas were characterised to upregulate core components of the SUMOylation machinery, including SUMO proteins, SAE1, SAE2, and UBC9. Inhibition of the SUMO pathway triggered a G2/M phase arrest of the cell cycle, polyploidy, and apoptosis in a MYC-specific manner. Genetic interference with the pathway by targeting SAE2 demonstrated therapeutic efficacy in murine and human B cell lymphoma models in vivo.90 Furthermore, the knockdown of SAE2 in SCLC cell lines with high MYC expression induced an increased therapeutic effect compared to lines with low expression of the oncogene.90 Work investigating the SUMO pathway in context of MYC showed that the SUMOylation pathway is required to cope with MYC-induced mitotic stress64 and that MYC hyperactivation in the context of SUMO inhibition results in irregular spindle activity, aneuploidy, and subsequent apoptosis.64 The concept is illustrated in Fig. 3.

In contrast to the well-known functions of MYC in the G1 or S phases of the cell cycle,91 the role of MYC in mitosis is less well understood. Cells with high MYC levels show morphologically altered spindles and are characterised by changes in the timing of mitotic progression.92 Furthermore, increased MYC expression is associated with misaligned chromosomes in metaphase with subsequent lagging chromosomes in anaphase.93 This association is relevant from the therapeutic view, as MYC was demonstrated to be a critical determinant of cell fates occurring upon the treatment of cells with various perturbations affecting mitosis.94–96 Such observations are clinically relevant, as demonstrated by the increased responsiveness of MYC-amplified breast cancers to docetaxel-containing neoadjuvant chemotherapies.97 Considering that the SAE inhibitor ML-792 interferes with mitotic progression and chromosome segregation,98 the increased potency of such SAE inhibitors in MYC-hyperactive solid cancers seems well explained.

At the molecular level, a 2020 study implicates the microtubule-binding protein targeting protein for Xenopus kinesin-like protein 2 (TPX2) as an MYC-associated synthetic lethal gene.99 TPX2 is required for spindle assembly during mitosis and the gene is directly activated by MYC. Whereas normal cells need low amounts of the protein for spindle assembly, cancer cell with high MYC expression depend on TPX2 to efficiently form the spindle and progress though mitosis.95 Importantly, the synthetic lethal interaction of MYC is not restricted to TPX2. Synthetic lethality between MYC hyperactivation and the mitosis regulators BIRC5/survivin and EGS/kinesin-5 was also demonstrated,93 and MYC-associated synthetic lethal screens were enriched for mitotic genes.64 Interestingly, many proteins identified in large-scale proteomic screens to harbour multiple SUMO sites are mitotic proteins, and BIRCS, EG5, and TPX2 can all be SUMOylated.95 In fact, 39 SUMO sites have been identified in TPX2.96 This high number could function to ensure proper spindle formation by stabilising interactions with other spindle factors. As SUMOylation plays an important role in the organisation of the spindle and
The SUMO pathway in pancreatic cancer: insights and inhibition

C Schneeweis et al.

Fig. 3 MYC and SUMO inhibitor sensitivity. The association of high MYC activity to the sensitivity of PDAC cells to SUMO inhibitors is depicted. Increased expression of MYC leads to mitotic alterations and generates vulnerabilities. Therefore, cancer cells with high MYC activity depend on safeguard pathways to cope with this particular stress. These safeguard pathways, which include the SUMOylation machinery, allow the cells to adapt to mitotic stress. Blocking the SUMO pathway induces G2/M phase cell cycle arrest, polyploidy, and subsequent cell death. Beyond the SUMO pathway, mitotic genes, like TPX2, BIRC5/survivin, and EG5/kinesin-5, can function as safeguards. Please see also the two recent publication of the Goga93 and Taylor92 laboratories for a detailed discussion.

FUTURE DIRECTIONS

First evidence implicates that SUMO PTM represents a dynamic biomarker for the response towards currently used chemotherapies. These findings offer the opportunity to validate the expression of PML, for example, and to measure its SUMOylation status in prospective clinical trials to select for chemotherapy responders. The data demonstrating that various cellular stresses induce dynamic SUMOylation and deSUMOylation events argue for systematically studying SUMOylation targets as well as the processes that are controlled by these events. This approach will provide information to develop novel molecular-informed and rational mechanism-based therapies. In addition, investigating the specific role of SENPs, which, in normal cells, tightly control the SUMOylation equilibrium, could provide information for additional pharmacological intervention in MYC/SUMO-activated PDAC and other cancers.

The development of SAE inhibitors clearly shows that specific inhibition of the SUMO pathway is feasible. Despite the critical importance of SUMOylation, SUMO inhibitors globally targeting SAE are well tolerated in preclinical models and Phase 1 clinical trials are currently ongoing. The investigation of such inhibitors in the clinic (e.g. TAK-981) and the development of novel highly specific SUMO inhibitors will allow for testing the principle of SUMO inhibition in molecularly informed translational applications. The efficacy of clinical SUMO inhibitors will, however, depend on the development of stratification concepts for selecting PDAC patients with tumours that are particularly sensitive to this approach.

Current data argue that SUMO inhibition is relevant for MYC-hyperactivated PDACs. However, not all PDAC models with evidence for MYC hyperactivation respond to the SAE inhibitors. This lack of response towards targeted therapies despite the selection by a molecular marker is typically seen in a portion of patients with gastrointestinal cancers in the clinic. However, biomarker-driven therapy selection has been successful in other cases. Therefore, to proceed with the concept of SAE inhibitors for PDAC, several additional issues must be addressed. First, the response of PDAC cells to SAE inhibitors must be analysed in greater functional detail, which might additionally allow to characterise the MYC-hyperactivated cancers with very high sensitivity towards SUMO inhibition. Furthermore, other markers in addition to MYC should be considered to define the SAE inhibitor-sensitive proportion of PDACs more precisely. Multivariate models have been shown to predict responses towards immunotherapies with high accuracy. Considering that the full oncogenic power of MYC is modulated by several co-factors, a similar approach might point to a path for defining multivariate predictive models. Clinical data from the past 5 years implicate the value of combining two or more targeted therapies to treat solid cancers as exemplified for colon cancer. Therefore, SAE inhibitor combination therapies could be developed in order to treat MYC-hyperactivated PDACs. The demonstration that ML-792 does not synergise with chemotherapies that act in the mitotic phase, including paclitaxel, argues for the need to systematically screen for such combination therapies. In addition, the first-in-class SUMO inhibitor, TAK-981, demonstrated immune-modulating properties. Considering that MYC mediates complex cross-talk between tumour cells and the tumour microenvironment, SUMO inhibitors should also be tested in autochthonous immune-proficient models.

ACKNOWLEDGEMENTS

We would like to apologise for not citing many more relevant and important reports due to lack of space, the need to selectively choose examples, or merely an oversight on our part.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting, conception, design, and writing of the review. All authors revised the manuscript for important intellectual content and approved the final version submitted for publication.
REFERENCES

1. Dureuix, M., Seufferlein, T., Laethem, J.-L., Laurent-Puig, P., Smolenschi, C., Malka, D. et al. Systemic treatment of pancreatic cancer revisited. Semin. Oncol. 46, 28–38 (2018).

2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).

3. Initiative, A. P. C. G., Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A-M. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).

4. Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S. et al. Molecular subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500–503 (2011).

5. Collisson, E. A., Bailey, P., Chang, D. K. & Bankani, A. V. Molecular subtypes of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 207–220 (2019).

6. Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. https://doi.org/10.1038/s41588-019-0566-9 (2020).

7. Brunton, H., Caligiuri, G., Cunningham, R., Upstill-Goddard, R., Bailey, U.-M., Garner, I. M. et al. HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Rep. 31, 107625 (2020).

8. Bärthel, S., Schneider, G. & Saur, D. Blocking the road to deSUMOylation in cell stress response. Annu. Rev. Biochem. 82, 357–385 (2013).

9. Hendriks, I. A. & Vertegaal, A. C. O. A comprehensive compilation of SUMO proteomics. Nat. Rev. Mol. Cell Biol. 17, 581–595 (2016).

10. Guo, C. & Henley, J. M. Wrestling with stress: roles of protein SUMOylation and deSUMOylation in cell stress response. JUBMB Life 66, 71–77 (2014).

11. Zhao, X. SUMO-mediated regulation of nuclear functions and signaling processes. Mol. Cell 71, 409–418 (2018).

12. Wang, L., Filipek, A. Non-nuclear function of sumoylated proteins. Biochem. Biophys. Acta 1843, 2878–2885 (2014).

13. Biedermann, A., Hasan, S., Schneeweis, C., Schick, M., Schneider, L., Muckenthaler, M. U. SUMO pathway in pancreatic cancer: insights and inhibition. Mol. Cancer J. 13, 2478–2494 (2014).

14. Chang, H. R., Munkhjargal, A., Kim, M.-J., Park, S. Y., Jung, E., Ryu, J. H. et al. The functional roles of PML nuclear bodies in genome maintenance. Mutat. Res. 809, 99–107 (2018).

15. Chien, W., Lee, K. L., Ding, L. W., Wusches, P., Kato, H., Doan, N. B. et al. PIA4S is an activator of hypoxia signalling via VHL suppression during growth of pancreatic cancer cells. Br. J. Cancer 109, 1795–1804 (2013).

16. Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500–503 (2011).

17. Collisson, E. A., Bailey, P., Chang, D. K. & Bankani, A. V. Molecular subtypes of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 207–220 (2019).

18. Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. https://doi.org/10.1038/s41588-019-0566-9 (2020).

19. Brunton, H., Caligiuri, G., Cunningham, R., Upstill-Goddard, R., Bailey, U.-M., Garner, I. M. et al. HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Rep. 31, 107625 (2020).

20. Bärthel, S., Schneider, G. & Saur, D. Blocking the road to deSUMOylation in cell stress response. Annu. Rev. Biochem. 82, 357–385 (2013).

21. Hendriks, I. A. & Vertegaal, A. C. O. A comprehensive compilation of SUMO proteomics. Nat. Rev. Mol. Cell Biol. 17, 581–595 (2016).

22. Guo, C. & Henley, J. M. Wrestling with stress: roles of protein SUMOylation and deSUMOylation in cell stress response. JUBMB Life 66, 71–77 (2014).
protein–protein interactions using Affimer (Adhrion) technology. Sci. Signal. 10, eaau2005 (2017).
45. Tiede, C., Tiede, C. A. G., Deacon, S. E., Mandal, U., Nettleship, J. E., Owen, R. L. et al. Adhrion: a stable and versatile peptide display scaffold for molecular recognition applications. Protein Eng. Des. Sel. 27, 145–155 (2014).
46. Tiede, C., Bedford, R., Heselton, S. J., Smith, G., Wijetunga, I., Ross, R. et al. Affimer technology: a versatile platform for therapeutic protein engineering. Biopolymers 95, 62–70 (2012).
47. Li, Y.-J., Perkins, A. L., Su, Y., Ma, Y., Colson, L., Horne, D. A. et al. Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation. Proc. Natl Acad. Sci. USA 109, 4092–4097 (2012).
48. Alontaga, A. Y., Li, Y., Chen, C.-H., Ma, C.-T., Malany, S., Key, D. E. et al. Design of high-throughput screening assays and identification of a SUMO1-specific small molecule chemotype targeting the SUMO-interacting motif-binding surface. ACS Comb. Sci. 17, 239–246 (2015).
49. Voet, A. R. D., Ito, A., Hirohama, M., Matsuoka, S., Tochio, N., Kigawa, T. et al. Discovery of small molecule inhibitors targeting the SUMO–SIM interaction using a protein interface consensus approach. MedChemComm 5, 783–786 (2014).
50. Dang, C. V. MYC on the path to cancer. Cell 149, 22–35 (2012).
51. Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
52. Brar, G., Blasi, E. M., Bender, R. J., Brody, J. R., Sohal, D. L., Madhavan, S. et al. Multimolecular comparison of primary versus metastatic pancreatic tumours. Br. J. Cancer 112, 264–270 (2015).
53. Hayashi, A., Fan, J., Chen, R., Ho, Y., Makohon-Moore, A. P., Leconte, N. et al. A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nat. Cancer 1, 59–74 (2020).
54. Hessmann, E., Schneider, G., Ellenrieder, V. & Sveke, J. T. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies. Oncogene 35, 1609–1618 (2015).
55. Wirth, M., Mahboobi, S., Kra mer, O. H. & Schneider, G. Concepts to target MYC in pancreatic cancer. Mol. Cancer Ther. 15, 1792–1798 (2016).
56. Wirth, M. & Schneider, G. MYC: a stratification marker for pancreatic cancer therapy. Trends Cancer 2, 1–3 (2016).
57. Cermelli, S., Jang, I. S., Bernard, B. & Grandori, C. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb. Perspect. Med. 4, a014209 (2014).
58. Ashworth, A. & Lord, C. J. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? Nat. Rev. Clin. Oncol. 15, 564–576 (2018).
59. Huang, A., Garraway, L. A., Ashworth, A. & Weber, B. Synthetic lethality as an integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03847495. Mol. Cancer Ther. 11, 710–719 (2012).
60. Wang, Y., Engels, I. H., Knee, D. A., Deveraux, Q. L. & Quon, K. C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5, 501–512 (2004).
61. Horiiuchi, D., Camarda, R., Zhou, A. Y., Yau, C., Momcilovic, O., Balakrishnan, S. et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat. Med. 17, 1321–1329 (2011).
62. Wang, J., Anderson, P. D., Luo, W., Giud, D., Roh, M. & Abdulkadir, S. A. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 31, 1794–1803 (2012).
63. Bian, B., Bigonnnet, M., Gayet, O., Loncle, C., Maigian, A., Gilabert, M. et al. Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol. Med. 9, 482–497 (2017).
64. Bian, B., Ju, N. A., Gayet, O., Bigonnnet, M., Brandonne, N., Roques, J. et al. Pancreatic cancer organoids for determining sensitivity to bromodomain and extra-terminal inhibitors (BETi). Front. Oncol. 9, 475 (2019).
65. Cervantes, M., Muro, A., Kondo, Y., Tang, X., Arriagada, R., Ribeiro, C. et al. MYC-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Proc. Natl Acad. Sci. USA 101, 10638–10643 (2004).
66. Perera, D. & Venkitaraman, A. R. Oncogenic KRAS triggers MAFK-dependent errors in mitosis and MYC-dependent sensitivity to mitotic-antagonists. Sci. Rep. 6, 29741 (2016).
67. Topham, C., Tighe, A., Ly, P., Bennett, A., Sloss, O., Nelson, L. et al. MYC is a major determinant of mitotic cell fate. Cancer Cell 28, 129–140 (2015).
68. Zhao, N., Cao, J., Xu, L., Tang, Q., Dobrolecki, L. E., Ly, X. et al. Pharmacological targeting of MYC-regulated IRE1XBPI pathway suppresses MYC-driven breast cancer. J. Clin. Investig. 128, 1283–1299 (2018).
69. Xie, H., Tang, C.-H. A., Song, J. H., Mancuso, A., Valle, J. R. D., Cao, J. et al. IRE1α-RNase–dependent lipid homeostasis promotes survival in MYC-transformed cancers. J. Clin. Investig. 128, 1300–1316 (2018).
70. Hoellstein, A., Fallahi, M., Schoeffmann, S., Steidle, S., Deveraux, Q. L. & Quon, K. C. MYC-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood 124, 2081–2090 (2014).
71. Liu, X., Xu, Y., Zhang, P., Guo, F., Qin, Q., Yin, T. et al. Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J. Hematol. Oncol. 8, 67 (2015).
72. Bretonnes, G., Delgada, M. D. & León, J. Myc and cell cycle control. Biochim. Biophys. Acta 1849, 506–516 (2014).
73. Little, S., Sloss, O., Garies, B., Pierce, A., Whetton, A. D. & Taylor, S. S. Oncogenic MYC amplifies mitotic perturbations. Open Biol. 9, 190136 (2019).
93. Rohrberg, J., Mark, D. V., de, Amouzgar, M., Lee, J. V., Taileb, M., Corella, A. et al. MYC dysregulates mitosis, revealing cancer vulnerabilities. Cell Rep. 30, 3358.e7–3362.e7 (2020).

94. Pereira, C. B. L., Leal, M. F., Abdelhay, E. S. F. W., Demachki, S., Assumpção, P. P., Souza, M. Cde et al. MYC amplification as a predictive factor of complete pathologic response to docetaxel-based neoadjuvant chemotherapy for breast cancer. Clin. Breast Cancer 17, 188–194 (2017).

95. Abriu, A. & Liakopoulos, D. How does SUMO participate in spindle organization? Cells 8, 801 (2019).

96. Hendriks, I. A., Lyon, D., Young, C., Jensen, L. J., Vertegaal, A. C. O. & Nielsen, M. L. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat. Struct. Mol. Biol. 24, 325–336 (2017).

97. Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S. et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY Umbrella Trial. Cancer Discov. 9, 1388–1405 (2019).

98. Kopetz, S., Grothey, A., Yaeger, R., Cutsem, E. V., Desai, J., Yoshino, T. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019).

99. Lee, J. S. & Ruppin, E. Multimics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA Oncol. 5, 1614–1618 (2019).

100. Magen, A., Sahu, A. D., Lee, J. S., Sharmin, M., Lugo, A., Gutkind, J. S. et al. Beyond synthetic lethality: charting the landscape of pairwise gene expression states associated with survival in cancer. Cell Rep. 28, 938.e6–948.e6 (2019).

101. Khattar, M., Song, K., Grossman, S., Xega, K., He, X., Idamakanti, N. et al. Abstract 3252: TAK-981: a first in class SUMO inhibitor in phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming. Cancer Res. https://doi.org/10.1158/1538-7445.am2019-3252 (2019).

102. Nakamura, A., Grossman, S., Song, K., Idamakanti, N., Shapiro, G. & Huszar, D. Abstract 1523: Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through type I IFN pathway activation. Cancer Res. https://doi.org/10.1158/1538-7445.am2019-1523 (2019).

103. Sodir, N. M., Kortlever, R. M., Barthet, V. J. A., Campos, T., Pellegrinet, L., Kupczak, S. et al. Myc instructs and maintains pancreatic adenocarcinoma phenotype. Cancer Discov. https://doi.org/10.1158/2159-8290.cd-19-0435 (2020).

104. Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A. et al. Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872–887 (2020).